Randomized phase III study of daratumumab (D) versus bortezomib plus D as a maintenance therapy after D-MPB for elderly or non-elderly patients refusing transplant with untreated multiple myeloma (JCOG1911, B-DASH study)

doi:10.1016/j.annonc.2023.10.734

Return

Randomized phase III study of daratumumab (D) versus bortezomib plus D as a maintenance therapy after D-MPB for elderly or non-elderly patients refusing transplant with untreated multiple myeloma (JCOG1911, B-DASH study)

2023-11-01

PRE

DOI：10.1016/j.annonc.2023.10.734

Original

Original request for help

Save

Abstract

Journal

Annals of Oncology

IF:

65.4

Papers:

3.4W

Citations:

6.4W

Organization

Japanese Foundation for Cancer Research

Scholars:

3.7K

Papers: 3.0K

Citations: 2.5K

national cancer center - japan

Scholars:

1.1W

Papers: 8.4K

Citations: 12

Keio University

Scholars:

2.2W

Papers: 1.6W

Citations: 13

nagoya medical center

Scholars:

904

Papers: 773

Citations: 0

Nagoya City University

Scholars:

5.8K

Papers: 4.6K

Citations: 3.3K

View more organizations